Geospiza, the Seattle-based maker of software for biological analysis, is announcing today that veteran drug developer Bruce Montgomery is joining its board of directors. Montgomery recently stepped down as senior vice president of respiratory drugs at Gilead Sciences, four years after he sold Seattle-based Corus Pharma to Gilead for $365 million. Geospiza’s chairman, Gordon Gardiner, said Montgomery will add expertise to the board as the company seeks to grow beyond its traditional base of academic research customers, and expand more into pharmaceutical R&D.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
